https://scholars.lib.ntu.edu.tw/handle/123456789/588341
標題: | Pharmacokinetics and dosing of vancomycin in patients undergoing sustained low efficiency daily diafiltration (SLEDD-f): A prospective study | 作者: | SHIN YI LIN LI-JIUAN SHEN VIN-CENT WU Ko W.-J. CHIEN-CHIH WU FE-LIN LIN WU |
公開日期: | 2021 | 出版社: | Elsevier B.V. | 卷: | 120 | 期: | 1 | 起(迄)頁: | 737-743 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Background/purpose: The pharmacokinetics of vancomycin in patients who undergo sustained low efficiency daily diafiltration (SLEDD-f) is not clear. This study aimed to determine the appropriate vancomycin dosage regimen for patients receiving SLEDD-f. Methods: This prospectively observational study enrolled critically ill patients older than 18 years old that used SLEDD-f as renal replacement therapy and received vancomycin treatment. An 8-h SLEDD-f was performed with FX-60 (high-flux helixone membrane, 1.4 m2). Serial blood samples were collected before, during, and after SLEDD-f to analyse vancomycin serum concentrations. Effluent fluid samples (a mixture of dialysate and ultrafiltrate) were also collected to determine the amount of vancomycin removal. Results: Seventeen patients were enrolled, and 10 completed the study. The amount of vancomycin removal was 447.4 ± 88.8 mg (about 78.4 ± 18.4% of the dose administered before SLEDD-f). The vancomycin concentration was reduced by 57.5 ± 14.9% during SLEDD-f, and this reduction was followed by a rebound with duration of one to three hours. The elimination half-life of vancomycin decreased from 64.1 ± 35.7 h before SLEDD-f to 7.0 ± 3.0 h during SLEDD-f. Conclusion: Significant amount of vancomycin removed during SLEDD-f. Despite the existence of post-dialysis rebound, a sufficient supplemental dose is necessary to maintain therapeutic range. ? 2020 Formosan Medical Association |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089825638&doi=10.1016%2fj.jfma.2020.08.011&partnerID=40&md5=10d6e6c70df05c7d2f7c02a8aa468cab https://scholars.lib.ntu.edu.tw/handle/123456789/588341 |
ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2020.08.011 | SDG/關鍵字: | heparin; vancomycin; antiinfective agent; vancomycin; acute kidney failure; adult; Article; blood sampling; clinical article; controlled study; critically ill patient; diafiltration; drug blood level; drug dose regimen; drug elimination; drug monitoring; effluent; elimination half-life; end stage renal disease; female; high performance liquid chromatography; human; infection control; loading drug dose; maintenance drug dose; male; medical care; observational study; pharmacokinetic parameters; prospective study; renal replacement therapy; sustained lowefficiency daily diafiltration; treatment duration; ultrafiltration; adolescent; critical illness; Acute Kidney Injury; Adolescent; Anti-Bacterial Agents; Critical Illness; Humans; Hybrid Renal Replacement Therapy; Prospective Studies; Vancomycin |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。